Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Sold by Silver Oak Advisory Group Inc.

Silver Oak Advisory Group Inc. decreased its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 13.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 777 shares of the medical research company’s stock after selling 120 shares during the period. Silver Oak Advisory Group Inc.’s holdings in Bio-Rad Laboratories were worth $251,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Treasurer of the State of North Carolina increased its position in Bio-Rad Laboratories by 0.4% in the 3rd quarter. Treasurer of the State of North Carolina now owns 9,491 shares of the medical research company’s stock worth $3,402,000 after purchasing an additional 40 shares during the last quarter. Teacher Retirement System of Texas increased its holdings in Bio-Rad Laboratories by 2.5% in the third quarter. Teacher Retirement System of Texas now owns 1,711 shares of the medical research company’s stock worth $613,000 after buying an additional 41 shares during the last quarter. Signaturefd LLC raised its position in Bio-Rad Laboratories by 15.8% during the fourth quarter. Signaturefd LLC now owns 352 shares of the medical research company’s stock valued at $114,000 after acquiring an additional 48 shares in the last quarter. Yousif Capital Management LLC lifted its stake in Bio-Rad Laboratories by 1.9% in the fourth quarter. Yousif Capital Management LLC now owns 2,775 shares of the medical research company’s stock valued at $896,000 after acquiring an additional 51 shares during the last quarter. Finally, HighTower Advisors LLC grew its position in Bio-Rad Laboratories by 0.7% in the third quarter. HighTower Advisors LLC now owns 7,258 shares of the medical research company’s stock worth $2,606,000 after acquiring an additional 54 shares in the last quarter. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on BIO shares. UBS Group lifted their price objective on shares of Bio-Rad Laboratories from $395.00 to $420.00 and gave the company a “buy” rating in a research note on Friday, February 16th. StockNews.com raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday. Royal Bank of Canada lowered their price objective on Bio-Rad Laboratories from $484.00 to $480.00 and set an “outperform” rating on the stock in a report on Friday, February 16th. Finally, Citigroup downgraded Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and cut their price objective for the company from $400.00 to $365.00 in a research note on Wednesday, April 3rd. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Bio-Rad Laboratories presently has an average rating of “Moderate Buy” and an average target price of $468.00.

Bio-Rad Laboratories Stock Performance

Bio-Rad Laboratories stock traded down $2.79 on Thursday, reaching $275.42. 164,771 shares of the stock were exchanged, compared to its average volume of 203,243. The stock has a market cap of $7.85 billion, a PE ratio of -12.82 and a beta of 0.87. The firm has a fifty day moving average price of $326.24 and a two-hundred day moving average price of $318.15. Bio-Rad Laboratories, Inc. has a twelve month low of $261.59 and a twelve month high of $473.50. The company has a current ratio of 5.83, a quick ratio of 4.34 and a debt-to-equity ratio of 0.14.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Thursday, February 15th. The medical research company reported $3.10 earnings per share for the quarter, topping the consensus estimate of $2.93 by $0.17. The business had revenue of $681.18 million during the quarter, compared to analysts’ expectations of $685.00 million. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 23.86%. The firm’s revenue was down 6.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.31 EPS. Sell-side analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.41 EPS for the current year.

Insider Transactions at Bio-Rad Laboratories

In other news, EVP Michael Crowley sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $336.00, for a total transaction of $1,008,000.00. Following the sale, the executive vice president now directly owns 6,942 shares in the company, valued at $2,332,512. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 17.06% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.